ArticleThe American journal of clinical nutrition2025
A scoping review on the possible immunometabolic properties of the furan fatty acid metabolite 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid.
Article in The American journal of clinical nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating levels of 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF), a metabolite derived from dietary furan fatty acids primarily found in marine food sources, have long been recognized as biomarkers for fish intake. However, elevated CMPF levels are also observed in patients with type 2 diabetes or chronic kidney disease and in healthy people, associated with a reduced infection risk, suggesting potential bioactive roles in metabolism and immune function. Yet, the possible causal mechanisms behind these associations are unknown. The aim of this scoping review, derived from human observations as well as in vivo and in vitro experimental studies, is to present the hypothesis that CMPF has immunometabolic properties by providing an overview of the determinants of circulating CMPF levels and presenting the studies suggesting its influence on cellular energy metabolism, particularly through enhancing lipid β-oxidation, potentially via activation of peroxisome proliferator-activated receptors (PPARs). CMPF notably affects hepatic metabolism by increasing mitochondrial fatty acid utilization and promoting the expression of hepatokines such as fibroblast growth factor 21, which may exert systemic metabolic and anti-inflammatory effects. Additionally, elevated CMPF levels have complex impacts on pancreatic function, potentially impairing insulin secretion and modifying glucose homeostasis. These metabolic alterations in the liver and pancreas can indirectly influence immune responses, shaping energy metabolism within immune cells and enhancing anti-inflammatory phenotypes. Moreover, CMPF may also directly influence immune cell metabolism and function through PPAR activation. Epidemiological evidence further supports that elevated CMPF levels are associated with reduced susceptibility to infections. Collectively, there is compelling evidence supporting the hypothesis that CMPF is a bioactive metabolite with systemic metabolic and immunomodulatory effects, warranting further in-depth investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.